Repositorio Dspace

Improvement in Quality of Life and Non-Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa

Mostrar el registro sencillo del ítem

dc.contributor.author Santos-García, Diego
dc.contributor.author Cerdán-Sánchez, María
dc.contributor.author Yanez-Bana, Rosa
dc.contributor.author Cabo, Iria
dc.contributor.author Cimas-Hernando, María-Iciar
dc.date.accessioned 2026-11-11T09:05:22Z
dc.date.available 2026-11-11T09:05:22Z
dc.date.issued 2026-08
dc.identifier.citation Santos García D, Cerdán Sánchez M, Yáñez Baña R, Cabo I, Cimas Hernando MI. Improvement in Quality of Life and Non-Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa. Euro J of Neurology. agosto de 2026;33(8):e70731. doi:10.1111/ene.70731
dc.identifier.issn 1351-5101
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/29159
dc.description.abstract BACKGROUND: CVT-301 (Inbrija) has demonstrated its effectiveness in treating OFF periods in people with Parkinson's disease (PwP). However, its effect on non-motor symptoms (NMS) and quality of life has not been researched yet. Our aim was to analyze the change observed in health-related quality of life (HRQoL) and, as a secondary exploratory analysis, NMS associated with OFF episodes in PwP treated with CVT-301. METHODS: INLEVO-LIFE PD (an open-label study of the effect of INhaled LEVOdopa on quality of LIFE and non-motor symptoms in Parkinson's Disease) is a prospective open-label study conducted in five centers in Spain. The change from baseline (V0) to the end of the observational period (12 ± 2 weeks) (V12w) in the 39-item Parkinson's Disease Quality of Life Questionnaire (PDQ-39) total score was the primary efficacy measure. RESULTS: Forty PD patients (age 62.3 ± 9.2 years; 55% males) were included between March/2024 and November/2025. At 12 weeks, 34 patients were using CVT-301 and completed the follow-up (85%). The PDQ39 total score decreased from 43.6 ± 24.2 at V0 to 31.4 ± 20.6 at V12w (p < 0.0001). A significant decrease was observed in the mean score of 4 domains of the PDQ39. NMS burden was reduced at v12w from the OFF state to 30, 60, and 90 min after using CVT-301 (p < 0.0001). Mean daily OFF time decreased by 1.6 ± 1.9 h (p < 0.0001). Adverse events related to CVT-301 were reported in 35% of the patients. CONCLUSION: HRQoL and NMS associated with OFF episodes improved in PwP after 12 weeks using CVT-301.
dc.language.iso eng
dc.publisher WILEY
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Parkinson Disease/drug therapy/psychology
dc.subject.mesh Quality of Life
dc.subject.mesh Levodopa/administration & dosage/pharmacology/therapeutic use
dc.subject.mesh Male
dc.subject.mesh Middle Aged
dc.subject.mesh Female
dc.subject.mesh Antiparkinson Agents/administration & dosage/pharmacology/therapeutic use
dc.subject.mesh Aged
dc.subject.mesh Administration, Inhalation
dc.subject.mesh Prospective Studies
dc.title Improvement in Quality of Life and Non-Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 42560077
dc.relation.publisherversion https://onlinelibrary.wiley.com/doi/10.1111/ene.70731
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1111/ene.70731
dc.journal.title European Journal of Neurology
dc.identifier.essn 1468-1331


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta